HASHICORP INC-CL A (HCP)

US4181001037 - Common Stock

26.95  -0.05 (-0.19%)

After market: 26.95 0 (0%)

Fundamental Rating

4

HCP gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 279 industry peers in the Software industry. While HCP has a great health rating, there are worries on its profitability. HCP is quite expensive at the moment. It does show a decent growth rate.



2

1. Profitability

1.1 Basic Checks

In the past year HCP has reported negative net income.
HCP had a negative operating cash flow in the past year.
In the past 5 years HCP always reported negative net income.
HCP had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -11.27%, HCP is in line with its industry, outperforming 45.68% of the companies in the same industry.
HCP has a Return On Equity (-15.72%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -11.27%
ROE -15.72%
ROIC N/A
ROA(3y)-15.33%
ROA(5y)-17.17%
ROE(3y)-20.37%
ROE(5y)-30.92%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

HCP's Gross Margin of 81.36% is amongst the best of the industry. HCP outperforms 86.69% of its industry peers.
HCP's Gross Margin has been stable in the last couple of years.
HCP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y-0.29%

8

2. Health

2.1 Basic Checks

HCP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HCP has been increased compared to 1 year ago.
HCP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

HCP has an Altman-Z score of 6.55. This indicates that HCP is financially healthy and has little risk of bankruptcy at the moment.
HCP's Altman-Z score of 6.55 is fine compared to the rest of the industry. HCP outperforms 75.18% of its industry peers.
HCP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.55
ROIC/WACCN/A
WACC9.35%

2.3 Liquidity

HCP has a Current Ratio of 3.50. This indicates that HCP is financially healthy and has no problem in meeting its short term obligations.
HCP's Current ratio of 3.50 is fine compared to the rest of the industry. HCP outperforms 78.78% of its industry peers.
HCP has a Quick Ratio of 3.50. This indicates that HCP is financially healthy and has no problem in meeting its short term obligations.
HCP has a better Quick ratio (3.50) than 78.78% of its industry peers.
Industry RankSector Rank
Current Ratio 3.5
Quick Ratio 3.5

6

3. Growth

3.1 Past

HCP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.33%, which is quite impressive.
HCP shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.53%.
Measured over the past years, HCP shows a very strong growth in Revenue. The Revenue has been growing by 61.00% on average per year.
EPS 1Y (TTM)83.33%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q171.43%
Revenue 1Y (TTM)22.53%
Revenue growth 3Y40.14%
Revenue growth 5Y61%
Revenue growth Q2Q14.72%

3.2 Future

HCP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 137.40% yearly.
Based on estimates for the next years, HCP will show a quite strong growth in Revenue. The Revenue will grow by 14.75% on average per year.
EPS Next Y257.38%
EPS Next 2Y137.4%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.58%
Revenue Next 2Y14.75%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HCP. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 190.27 indicates a quite expensive valuation of HCP.
HCP's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 22.79. HCP is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 190.27

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HCP's earnings are expected to grow with 137.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y137.4%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

HCP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

HASHICORP INC-CL A

NASDAQ:HCP (3/28/2024, 8:15:03 PM)

After market: 26.95 0 (0%)

26.95

-0.05 (-0.19%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.37B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 190.27
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.27%
ROE -15.72%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 81.36%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.5
Quick Ratio 3.5
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)83.33%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y257.38%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)22.53%
Revenue growth 3Y40.14%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y